Literature DB >> 12162932

Clinical implications of statin event trials.

Anne Carol Goldberg1.   

Abstract

Event trials using statin therapy have shown a beneficial effect on rates of cardiovascular events. The three statins that have been used in long-term trials have shown generally similar effects on rates of myocardial infarction, stroke, revascularizations, and mortality. Safety data appear to be comparable for lovastatin, pravastatin, and simvastatin. Long-term trials of other statins are in progress or pending. The question of how much low-density lipoprotein cholesterol should be lowered may be answered by studies currently in progress.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162932     DOI: 10.1007/s11883-002-0070-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  24 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.

Authors:  G L Knatterud; Y Rosenberg; L Campeau; N L Geller; D B Hunninghake; S A Forman; J S Forrester; F L Gobel; J A Herd; A Hickey; B J Hoogwerf; M L Terrin; C White
Journal:  Circulation       Date:  2000-07-11       Impact factor: 29.690

3.  Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease.

Authors:  G R Thompson; J Hollyer; D D Waters
Journal:  Curr Opin Lipidol       Date:  1995-12       Impact factor: 4.776

Review 4.  "The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?.

Authors:  T A Jacobson
Journal:  Ann Intern Med       Date:  2000-10-03       Impact factor: 25.391

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  The MRC/BHF Heart Protection Study: preliminary results.

Authors:  Rory Collins; Richard Peto; Jane Armitage
Journal:  Int J Clin Pract       Date:  2002 Jan-Feb       Impact factor: 2.503

7.  Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.

Authors: 
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

8.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.